Literature DB >> 12069974

Experimental acute otitis media due to nontypeable Haemophilus influenzae: comparison of high and low azithromycin doses with placebo.

Franz E Babl1, Stephen I Pelton, Zhong Li.   

Abstract

Treatment of acute otitis media (AOM) with azithromycin results in apparent clinical success, but tympanocentesis performed 4 to 6 days after initiation of therapy in children with nontypeable Haemophilus influenzae (NTHI) recovered from initial middle ear cultures demonstrates persistence of infection in more than 50% of episodes. We sought to determine the effect of azithromycin at different doses on the density of middle ear infection due to NTHI to provide additional understanding of this dichotomy between clinical and microbiologic outcome measures in AOM. In a chinchilla model of experimental otitis media (EOM), animals treated with placebo were compared to animals receiving a single daily dose 30 or 120 mg of azithromycin per kg of body weight per day for 5 days. Microbiologic outcome was assessed by obtaining quantitative cultures from the middle ear during a 5-day course and for 1 week following therapy. Azithromycin concentrations were measured to ascertain whether a concentration-dependent effect was present. Azithromycin at 30 and 120 mg/kg/day demonstrated a dose-dependent effect on the quantitative assessment of middle ear infection due to NTHI. A 30-mg/kg dose of azithromycin daily resulted in levels in serum and areas under the serum concentration-time curve at 24 h comparable to published data obtained with children given azithromycin at 5 to 10 mg/kg in multiday regimens. Increased doses of azithromycin (120 mg/kg) achieved 2.5- to 4-fold-higher levels in serum and 3- to 6-fold-higher total levels and levels in extracellular middle ear fluid as well as more rapid reduction in bacterial density and a greater proportion of middle ears with complete sterilization than either placebo or the 30-mg/kg/day regimen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12069974      PMCID: PMC127299          DOI: 10.1128/AAC.46.7.2194-2199.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  23 in total

1.  Is the pneumococcus the one and only in acute otitis media?

Authors:  D Musher; R Dagan
Journal:  Pediatr Infect Dis J       Date:  2000-05       Impact factor: 2.129

2.  Pharmacokinetics of azithromycin administered alone and with atovaquone in human immunodeficiency virus-infected children. The ACTG 254 Team.

Authors:  L Y Ngo; R Yogev; W M Dankner; W T Hughes; S Burchett; J Xu; B Sadler; J D Unadkat
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

3.  Efficacy of a new macrolide (azithromycin). For acute otitis media in the chinchilla model.

Authors:  K H Chan; J D Swarts; W J Doyle; K Tanpowpong; D R Kardatzke
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1988-11

4.  Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.

Authors:  R Dagan; C E Johnson; S McLinn; N Abughali; J Feris; E Leibovitz; D J Burch; M R Jacobs
Journal:  Pediatr Infect Dis J       Date:  2000-02       Impact factor: 2.129

5.  Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children.

Authors:  R Dagan; E Leibovitz; D M Fliss; A Leiberman; M R Jacobs; W Craig; P Yagupsky
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

6.  In vitro and in vivo uptake of azithromycin (CP-62,993) by phagocytic cells: possible mechanism of delivery and release at sites of infection.

Authors:  R P Gladue; G M Bright; R E Isaacson; M F Newborg
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

7.  Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children.

Authors:  U B Schaad
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

8.  A comparative study of azithromycin and amoxycillin in paediatric patients with acute otitis media.

Authors:  E Mohs; A Rodriguez-Solares; E Rivas; Z el Hoshy
Journal:  J Antimicrob Chemother       Date:  1993-06       Impact factor: 5.790

9.  Modification of otitis media in chinchillas rechallenged with nontypable Haemophilus influenzae and serological response to outer membrane antigens.

Authors:  R B Karasic; C E Trumpp; H E Gnehm; P A Rice; S I Pelton
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

10.  Host factors and early therapeutic response in acute otitis media.

Authors:  S A Carlin; C D Marchant; P A Shurin; C E Johnson; D M Super; J M Rehmus
Journal:  J Pediatr       Date:  1991-02       Impact factor: 4.406

View more
  19 in total

1.  Study design questions in treatment of children with acute otitis media.

Authors:  Alejandro Hoberman; Jack L Paradise
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

2.  Novel, single-dose microsphere formulation of azithromycin versus 7-day levofloxacin therapy for treatment of mild to moderate community-acquired Pneumonia in adults.

Authors:  Joseph D'Ignazio; Marco A Camere; Drew E Lewis; Daniel Jorgensen; Jeanne D Breen
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  The chinchilla microdialysis model for the study of antibiotic distribution to middle ear fluid.

Authors:  Belinda W Y Cheung; Wei Liu; Ping Ji; Linda L Cartier; Zhihong Li; Nael Mostafa; Ronald J Sawchuk
Journal:  AAPS J       Date:  2006-02-03       Impact factor: 4.009

4.  Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media.

Authors:  Magali Leroy; Howard Cabral; Marisol Figueira; Valérie Bouchet; Heather Huot; Sanjay Ram; Stephen I Pelton; Richard Goldstein
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

Review 5.  Vaccines for Nontypeable Haemophilus influenzae: the Future Is Now.

Authors:  Timothy F Murphy
Journal:  Clin Vaccine Immunol       Date:  2015-03-18

6.  Effect of azithromycin on enhancement of methane production from waste activated sludge.

Authors:  Minh Tuan Nguyen; Toshinari Maeda; Mohd Zulkhairi Mohd Yusoff; Hiroaki I Ogawa
Journal:  J Ind Microbiol Biotechnol       Date:  2014-05-03       Impact factor: 3.346

7.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

8.  Application of capillary electrophoresis mass spectrometry and liquid chromatography multiple-step tandem electrospray mass spectrometry to profile glycoform expression during Haemophilus influenzae pathogenesis in the chinchilla model of experimental otitis media.

Authors:  Susanna L Lundström; Jianjun Li; Martin Månsson; Marisol Figueira; Magali Leroy; Richard Goldstein; Derek W Hood; E Richard Moxon; James C Richards; Elke K H Schweda
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  Sialic acid mediated transcriptional modulation of a highly conserved sialometabolism gene cluster in Haemophilus influenzae and its effect on virulence.

Authors:  Gaynor A Jenkins; Marisol Figueira; Gaurav A Kumar; Wendy A Sweetman; Katherine Makepeace; Stephen I Pelton; Richard Moxon; Derek W Hood
Journal:  BMC Microbiol       Date:  2010-02-16       Impact factor: 3.605

10.  High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.

Authors:  Antonio Arrieta; Adriano Arguedas; Pilar Fernandez; Stan L Block; Paz Emperanza; Sergio L Vargas; William A Erhardt; Pascal J de Caprariis; Constance D Rothermel
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.